September 15 (Hfrance.fr) - Pfizer Inc (PFE.N) stated that regulators Americans fromare expected to approve a third booster dose of the COVID-19 vaccine it developed with German company BioNTech SA six months after the second dose due to waning effectiveness of the shot over time, according to documents the drugmaker submitted to the US Food and Drug Administration. The FDA released the documents Wednesday ahead of an expert panel meeting on Friday to vote on whether or not to recommend that U.S. regulators approve the additional injections. Pfizer said data from its own trials showed that the vaccine's effectiveness decreased by about 6 percent every two months after the second dose. He also indicated that the incidence of breakthrough cases in this trial was higher in people who received their injections earlier. The manufacturer of mdrugs also pointed out real-world data from Israel and the United States show declining vaccine effectiveness. He said that a clinical trial of around 300 participants showed that the third dose generated a better immune response than the second dose. He also highlighted data from the recently launched booster program in Israel to show that a third dose restores high levels of protection against the virus. The FDA has yet to release the briefing with its perspective on the matter. Michael Erman Report Edited by Chizu Nomiyama and Nick Zieminski Our Standards: Thomson Hfrance.fr trust principles.